$LFCR News

Lifecore Biomedical Signs Manufacturing Services Agreement To Perform Process Development And Technical Transfer Services In Support Of Anticipated Commercial Manufacturing Upon Regulatory Approval

Lifecore Biomedical, Inc. (LFCR) Q1 2026 Earnings Call Transcript

Lifecore Biomedical, Inc. 2026 Q1 - Results - Earnings Call Presentation

Lifecore Biomedical Q1 Earnings Call Highlights

Lifecore Biomedical (NASDAQ:LFCR) Posts Q1 Revenue Miss and Wider-Than-Expected Loss

Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update

Lifecore Biomedical Q1 2026 Earnings Call Transcript

Lifecore Biomedical Affirms FY2026 Sales Guidance of $120.000M-$125.000M vs $122.430M Est

Lifecore Biomedical Q1 EPS $(0.43) Misses $(0.24) Estimate, Sales $23.193M Miss $26.501M Estimate

Lifecore Biomedical to Report Financial Results for the First Quarter Ended March 31, 2026, on May 6, 2026

Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6

Laughing Water Capital’s Insights on Lifecore Biomedical (LFCR)

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Lifecore Biomedical to Participate at 12th Annual American Biomanufacturing Summit

When Should You Buy Lifecore Biomedical, Inc. (NASDAQ:LFCR)?

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer

Lifecore Expands Manufacturing Deal With Existing Pharma Client

Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company

Lifecore Biomedical CEO: Standalone CDMO Shift Complete, Utilization to Hit 60% by 2029